Post-April 15, Where You Live Matters More Than You Think
Federal peptide reclassification sets the floor; state pharmacy boards set the ceiling. Ten states plus DC keep restrictive regimes that add real friction.
Read → FDA reclassification · April 15, 2026
The peptide category just changed. We cover it like a research desk.
Daily regulatory coverage, state-by-state legal tracking, compound-by-compound research, and a vetted pharmacy directory — for the 12 peptides the FDA reclassified on April 15, 2026.
Independent. No affiliate commissions from pharmacies. No telehealth sponsorships. Funded by reader subscriptions and educational products.
The window is open for about 90 days.
On April 15, 2026, the FDA moved 12 therapeutic peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF — out of Category 2. On July 23–24, 2026, the Pharmacy Compounding Advisory Committee finalizes their placement on the 503A Bulks List. Between those two dates, the entire peptide supply chain is pivoting from gray market to legitimate compounding industry. The 90 days before the public wave arrives is when the informed move is made.
Latest from the news desk
The Telehealth Brands Most Likely to Pivot Into Peptides After PCAC
GLP-1 telehealth providers have the prescribers, compounding ties, and DTC marketing muscle to dominate peptides after PCAC. Who's positioning, and the impact.
Read →BPC-157: What the Research Actually Shows (And What It Doesn't)
BPC-157 has the strongest practitioner reputation of the reclassified peptides. An honest read on preclinical breadth, human trial gaps, and what it means.
Read →Four lanes. One editorial desk.
Daily News Desk
Regulatory updates, industry moves, research summaries. Two to four pieces per day, tightly summarized, lightly reviewed.
Latest news →Regulatory Tracker
The FDA timeline, the July PCAC preview, a state-by-state legal snapshot updated as changes surface.
Open the tracker →Compound Research Library
Long-form pillars on all 12 peptides. What the research shows, what the safety data says, what legitimate sourcing looks like.
Browse compounds →Pharmacy & Provider Directory
Vetted compounding pharmacies and peptide-familiar prescribers, scored against a 10-point checklist, filterable by state.
Open the directory → Educational product · $27
The 2026 Peptide Law Playbook
60 pages. Five parts. The April 15 reclassification in plain English, a compound-by-compound decision guide, the 10-point pharmacy checklist, state-by-state legal snapshot, and the goal-organized playbooks for recovery, longevity, cognitive, skin, and immune use cases.
Post-PCAC update (July) included free.
Or skim the free Chapter 7 — 10-Point Pharmacy Checklist.
The 12 Peptides — Research, Regulatory Status, Sourcing.
Each pillar is a complete guide, updated as the regulatory picture clarifies.
BPC-157
Recovery and tissue repair. Most-studied on the list.
TB-500
Tissue repair, often paired with BPC-157.
KPV
Gut and skin anti-inflammatory.
MOTS-c
Mitochondrial and longevity-oriented.
DSIP
Sleep architecture and stress.
Semax
Cognitive, with a Russian clinical history.
Epitalon
Longevity and telomere research.
GHK-Cu
Skin, hair, tissue. Most cosmetic evidence base.
Melanotan II
Pigmentation. The most controversial on the list.
LL-37
Immune and antimicrobial.
Dihexa
Cognitive nootropic. Strong preclinical, weak human data.
PEG-MGF
Muscle recovery. On the WADA prohibited list.
Check your state.
Compounding pharmacy access varies meaningfully by state. Fifty-one pages, kept current, with the friction points and verified pharmacies for each.
Why this site exists and how it's funded.
PeptidesBeat is an independent editorial desk, not a telehealth brand and not a peptide seller. We do not accept affiliate commissions from compounding pharmacies. We do not accept sponsored content from peptide-adjacent telehealth companies. Our revenue comes from educational products like the Peptide Law Playbook and from a forthcoming paid-newsletter tier. That model keeps our incentives aligned with readers, not advertisers.
We cite primary sources. We distinguish preclinical research from human clinical trials. We don't prescribe, we don't recommend dosing, and we route every clinical question back to licensed practitioners.